Allakos Inc. ALLK
Set alert
0.33 0.00 0.00%
At close · May 15
0.3291 Day range 0.3291
52-week range unavailable
- YTD
- -72.80%
- 1 year
- -72.34%
- Open
- 0.3291
- Prev close
- 0.3291
- Mkt cap
- 113.47M
- Vol
- 1.31M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3291
- High
- 0.3291
- Forward P/E
- -2.02
- Beta
- 1.02
- Short ratio
- 1.78
- Inst. own
- 81.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 1.10
- 200-d avg
- 1.00
- 1y target
- 3.35
2Y chart
Events in this range
- Jan 17, 2024Rating: Barclays · Underweight → Underweight
- Jan 17, 2024Rating: JMP Securities · Market Outperform → Market Outperform
- Mar 14, 2024Earnings: -0.71; estimate -0.53; surprise -33.96%
- May 9, 2024Earnings: -0.5; estimate -0.41; surprise -21.95%
- May 9, 2024Earnings: —; estimate -0.41; surprise —%
- Jun 20, 2024Rating: Cantor Fitzgerald · — → Neutral
- Jun 26, 2024Rating: JMP Securities · Market Outperform → Market Outperform
- Jul 18, 2024Rating: Jefferies · Hold → Hold
- Aug 7, 2024Earnings: -0.3; estimate -0.32; surprise 6.25%
- Aug 7, 2024Earnings: —; estimate -0.32; surprise —%
- Sep 26, 2024Rating: JMP Securities · Market Outperform → Market Outperform
- Nov 6, 2024Earnings: -0.21; estimate -0.22; surprise 4.55%
Signals (81)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 2, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| RSI: Oversold | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 24, 2025 | 1 year ago |
| SMA: Bearish | Jan 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 23, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| SMA: Bearish | Jan 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 6, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 19, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 11, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 6, 2024 | 1 year ago |
| SMA: Bullish | Nov 29, 2024 | 1 year ago |
| SMA: Bullish | Nov 27, 2024 | 1 year ago |
| SMA: Bearish | Nov 22, 2024 | 1 year ago |
| SMA: Bearish | Nov 19, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 13, 2024 | 1 year ago |
| RSI: Overbought | Nov 11, 2024 | 1 year ago |
| RSI: Overbought | Nov 5, 2024 | 1 year ago |
| RSI: Overbought | Oct 25, 2024 | 2 years ago |
| SMA: Bullish | Oct 24, 2024 | 2 years ago |
| SMA: Bearish | Oct 23, 2024 | 2 years ago |
| SMA: Bullish | Oct 22, 2024 | 2 years ago |
| RSI: Overbought | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 16, 2024 | 2 years ago |
| SMA: Bearish | Oct 15, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| SMA: Bearish | Oct 8, 2024 | 2 years ago |
| SMA: Bullish | Oct 4, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 25, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 9, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 20, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 7, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 23, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 19, 2024 | 2 years ago |
| RSI: Oversold | Jul 19, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 16, 2024 | 2 years ago |
| RSI: Oversold | Jul 3, 2024 | 2 years ago |
| SMA: Bearish | Jun 25, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | Jun 14, 2024 | 2 years ago |
| SMA: Bullish | Jun 10, 2024 | 2 years ago |
| SMA: Bearish | Jun 4, 2024 | 2 years ago |
| MACD: Sell Signal | May 30, 2024 | 2 years ago |
| SMA: Bullish | May 16, 2024 | 2 years ago |
| SMA: Bearish | May 14, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| SMA: Bearish | May 10, 2024 | 2 years ago |
| SMA: Bullish | May 8, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 29, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 5, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 3, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 1, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 22, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 18, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 5, 2024 | 2 years ago |
| SMA: Bearish | Jan 16, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 16, 2024 | 2 years ago |
| RSI: Oversold | Jan 16, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 9, 2024 | 2 years ago |
| MACD: Sell Signal | Dec 20, 2023 | 2 years ago |
| RSI: Overbought | Dec 13, 2023 | 2 years ago |
| RSI: Overbought | Dec 4, 2023 | 2 years ago |
| SMA: Bullish | Nov 29, 2023 | 2 years ago |
| RSI: Oversold | Oct 27, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 25, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 20, 2023 | 3 years ago |
| RSI: Oversold | Oct 20, 2023 | 3 years ago |
| RSI: Oversold | Sep 11, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 5, 2023 | 3 years ago |
| RSI: Oversold | Aug 17, 2023 | 3 years ago |
| SMA: Bearish | Aug 10, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 10, 2023 | 3 years ago |
| RSI: Overbought | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 28, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 7, 2023 | 3 years ago |
Key statistics
- Market cap
- 113.47M
- Enterprise value
- 53.50M
- Trailing P/E
- 0.00
- Forward P/E
- -2.02
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.56
- EPS (TTM)
- -2.03
- Beta
- 1.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -53.34M
- Total cash
- 92.72M
- Total debt
- 39.00M
- Return on equity
- -121.68%
- Shares outstanding
- 89.34M
- Short % of float
- 1.59%
- 50-day average
- 1.10
- 200-day average
- 1.00
Analyst view
Consensus: hold
Hold
Price target (mean) 3.35 +917.9% upside
Now 0.3291
- Target (low)
- 1.40
- Target (mean)
- 3.35
- Target (high)
- 7.00
Ratings (0m) 7 2 buy · 5 hold · 0 sell
- Strong buy2
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.1775.
Financials — quick view
ALLK Revenue — quarterly 0
ALLK Net income — quarterly -26.18M
ALLK EPS — quarterly -0.29
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.22 | -0.21 | +0.01 | +4.55% |
| Aug 7, 2024 | Jun 1, 2024 | -0.32 | -0.30 | +0.02 | +6.25% |
| Aug 7, 2024 | Jun 1, 2024 | -0.32 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.41 | -0.50 | -0.09 | -21.95% |
| May 9, 2024 | Mar 1, 2024 | -0.41 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | -0.53 | -0.71 | -0.18 | -33.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jul 18, 2024 | Jefferies | main | Hold | Hold |
| Jun 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 20, 2024 | Cantor Fitzgerald | reit | — | Neutral |
| Jan 17, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jan 17, 2024 | Barclays | main | Underweight | Underweight |
About Allakos Inc.
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- allakos.com
News
- $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders
- Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
- Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
- Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
- Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
- Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Is Allakos Stock Plunging On Monday?
Your note
Sign in to keep a note on ALLK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDER ROBERT ALLEN | Chief Executive Officer | Stock Award(Grant) | Jan 5, 2023 | 1,376,990 |
| PATERSON CRAIG A. | Officer | Stock Award(Grant) | Jan 5, 2023 | 372,474 |
| RADFORD HARLAN BAIRD III | Chief Financial Officer | Sale | Jun 27, 2024 | 204,390 |
| TOMASI ADAM | President | Stock Award(Grant) | Jan 5, 2023 | 748,687 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 18.53% | 16,552,417 | 21.02M | Sep 29, 2024 |
| NEA Management Company, LLC | 6.88% | 6,147,260 | 7.81M | Sep 29, 2024 |
| FMR, LLC | 6.01% | 5,370,247 | 6.82M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.60% | 5,000,000 | 6.35M | Sep 29, 2024 |
| Vanguard Group Inc | 3.93% | 3,514,345 | 4.46M | Sep 29, 2024 |
| Redmile Group, LLC | 3.44% | 3,077,828 | 3.91M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Advisor Biotechnology Fund | 5.44% | 4,856,700 | 6.17M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.62% | 2,340,161 | 2.97M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.13% | 1,009,952 | 1.28M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 433,254 | 550.23K | Oct 30, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.38% | 338,198 | 429.51K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.20% | 180,630 | 229.40K | Oct 30, 2024 |